Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653340 | PMC |
| http://dx.doi.org/10.1111/bjh.17813 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China.
Front Med (Lausanne)
December 2024
Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
Objective: The aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden understanding of Omicron subvariant infections.
Method: A total of 244 individuals with Omicron subvariant (BA.2.
Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
Antiviral Res
February 2025
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, 510530, China; Guangzhou Henovcom Bioscience Inc, 11 Kaiyuan Rd, Guangzhou, Guangdong, China. Electronic address:
Article Synopsis
- The COVID-19 pandemic, driven by the SARS-CoV-2 virus, poses ongoing health risks and highlights the need for new antiviral treatments due to the virus's ability to mutate.
- Researchers designed and synthesized new 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs to inhibit the replication of SARS-CoV-2.
- Among these, nucleoside analog 11q showed the strongest antiviral effects, outperforming existing treatments like Remdesivir and indicating its potential as a future therapeutic option.
Molecular phenotypes of critical illness confer prognostic and biological enrichment in sub-Saharan Africa: a prospective cohort study from Uganda.
Thorax
December 2024
Department of Arbovirology, Emerging and Re-emerging Infectious Diseases, Uganda Virus Research Institute, Entebbe, Uganda.
The generalisability of critical illness molecular phenotypes to low- and middle-income countries (LMICs) is unknown. We show that molecular phenotypes derived in high-income countries (hyperinflammatory and hypoinflammatory, reactive and uninflamed) stratify sepsis patients in Uganda by physiological severity, mortality risk and dysregulation of key pathobiological domains. A classifier model including data available at the LMIC bedside modestly discriminated phenotype assignment (area under the receiver operating characteristic curve (AUROC) 0.
View Article and Find Full Text PDFNavigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.
Molecules
November 2024
Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.
Amidst the ongoing global challenge of the SARS-CoV-2 pandemic, the quest for effective antiviral medications remains paramount. This comprehensive review delves into the dynamic landscape of FDA-approved medications repurposed for COVID-19, categorized as antiviral and non-antiviral agents. Our focus extends beyond conventional narratives, encompassing vaccination targets, repurposing efficacy, clinical studies, innovative treatment modalities, and future outlooks.
View Article and Find Full Text PDFDe novo myasthenia gravis in a patient with malignant melanoma after concurrent SARS-CoV-2 vaccination and immune checkpoint inhibitor therapy: Case report and literature review.
eNeurologicalSci
December 2024
ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- * Due to the COVID-19 pandemic, cancer patients were prioritized for vaccination, despite not being included in vaccine trials, raising concerns about potential autoimmune responses when vaccinated while on ICIs.
- * A case study is presented of a melanoma patient who developed fatal myasthenia gravis after receiving the inactivated Sinopharm COVID-19 vaccine along with pembrolizumab, highlighting safety concerns and the need for further research on vaccines and irAEs in ICI-treated patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!